Novartis backs brolucizumab with new head-to-head Eylea trial

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 9, 2019 at 8:32 PM.

  1. #1 cafead, Sep 9, 2019 at 8:32 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,167
    Likes Received:
    3
    via Novartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Eylea, the market leader.

    article source
     
    Quote

Reply to Thread